AC
INDP icon

Armistice Capital’s Indaptus Therapeutics INDP Stock Holding History

Armistice Capital’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-13,639
Closed -$2.99M – 158
2021
Q3 		$2.99M Buy
+13,639
New +$3.94M 0.05% 114

Other funds holding INDP

SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHL
Investment House LLC Redondo Beach, California $2.21B AUM 39.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $18.2B AUM 22.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return

Armistice Capital's INDP Position: Q4 2021 in Review

Armistice Capital sold out of Indaptus Therapeutics (INDP) in Q4 2021, closing a stake of 13,639 shares — an estimated $2.99M sold.

Armistice Capital first reported a position in INDP in Q3 2021 and held it in 1 quarter. The position peaked at $2.99M in Q3 2021. 14 funds tracked by Wall St. Rank hold INDP as of Q4 2021.

  • Armistice Capital reported no remaining Indaptus Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Armistice Capital sold 13,639 Indaptus Therapeutics shares in Q4 2021, an estimated $2.99M.
  • Armistice Capital first reported a position in Indaptus Therapeutics in Q3 2021 and held it in 1 quarter.
  • Armistice Capital's Indaptus Therapeutics position peaked at $2.99M in Q3 2021.
  • 14 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q4 2021.

Based on Armistice Capital's 13F filing for Q4 2021, filed 14 Feb 2022.